FDA's 503B Exclusion: The April 2026 Move That Ends Large-Scale GLP-1 Compounding

On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. If finalized, outsourcing facilities can never again compound these drugs from bulk ingredients — regardless of future market conditions. The comment deadline is June 29, 2026.

The Federal Register notice published on May 1, 2026 — 41 pages, docket number 2026-08552 — is the most consequential regulatory action in the compounded GLP-1 market since the FDA declared the semaglutide shortage resolved in February 2025. The FDA proposed not to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List, finding no clinical need for outsourcing facilities to compound these drugs from bulk drug substances.

This is not a suggestion. If finalized, it permanently closes one of the two legal pathways that allowed large-scale compounding of GLP-1 medications. The other pathway — drug shortage listings — was already shut down for semaglutide (resolved February 2025) and tirzepatide (resolved 2024). Only liraglutide remains on the shortage list as of this writing.

What Exactly Is the 503B Bulks List?

Section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), enacted after the 2013 New England Compounding Center meningitis outbreak that killed dozens of people, established a framework for FDA-registered outsourcing facilities. These are not traditional pharmacies — they manufacture large batches of compounded drugs for distribution to healthcare entities without individual patient prescriptions.

Under 503B, outsourcing facilities can only compound from bulk drug substances if: (a) the substance appears on the 503B Bulks List (determined by clinical need), or (b) the finished compounded drug corresponds to a product on the FDA's drug shortage list at the time of compounding, distribution, and dispensing.

The FDA's April 30 proposal addresses pathway (a). By not placing semaglutide, tirzepatide, and liraglutide on the Bulks List, the agency removes the only remaining legal basis for 503B compounding once the shortage pathway is closed.

The Regulatory Timeline

What the FDA's Rationale Says

The agency evaluated nominations from stakeholders arguing that compounded versions serve clinical needs that FDA-approved products do not. The FDA rejected those arguments. Specifically, the agency found no evidence that the oral and injectable forms of FDA-approved semaglutide products are medically unsuitable for certain patients, or that compounded buccal or sublingual formulations would address an unmet clinical need.

Critically, the FDA explicitly rejected affordability and insurance access as constituting "clinical need" under the statute. The agency's position is that cost is a market issue, not a clinical one — and the legal standard for the 503B Bulks List requires a demonstration of medical necessity, not economic necessity.

Who Gets Hit Hardest

The immediate impact falls on 503B outsourcing facilities that built their businesses around large-batch GLP-1 compounding during the shortage era. Telehealth platforms — including Hims & Hers, Ro, and LifeMD — that partnered with 503B compounders for medication supply face a forced economic transition. Cash-pay obesity clinics offering compounded GLP-1s at substantially lower prices than branded products will need to find alternative supply chains or shift to FDA-approved products.

At peak in 2024, compounded GLP-1s accounted for roughly 30% of the US supply. The branded alternatives carry drastically higher list prices: Wegovy at approximately $1,349/month and Zepbound at roughly $1,086/month for lower doses, compared to $150–$400/month for compounded versions.

The Legal Challenges

The Outsourcing Facilities Association and several compounding pharmacies have filed legal challenges against the FDA's shortage determination authority in the 5th Circuit. Those cases are unresolved. Whether the courts will intervene on the 503B Bulks List decision — a separate regulatory mechanism — remains to be seen.

The FDA has 60 days of public comment to consider before making a final determination. If finalized, the rule would prohibit 503B outsourcing facilities from compounding these agents from bulk substances under any circumstances, regardless of future market conditions.